{"contentid": 488010, "importid": NaN, "name": "Bayer anticipates immediate pharma bounce back after 2024 blip", "introduction": "German company Bayer is confident that it can bounce back from a decline in the Pharmaceuticals division\u00e2\u0080\u0099s sales in 2024 due to the patent expirations for established blockbusters Xarelto (rivaroxaban) and Eylea (aflibercept).", "content": "<p>German company Bayer (BAYN: DE) is confident that it can bounce back from a decline in the Pharmaceuticals division&rsquo;s sales in 2024 due to the patent expirations for established blockbusters Xarelto (rivaroxaban) and Eylea (aflibercept).</p>\n<p>Making the forecasts at its Capital Markets Day for 2021 on Wednesday, Bayer predicts the Pharmaceuticals Division will post robust annual sales growth of 3% to 5% through 2023.</p>\n<p>But, in 2024, Bayer anticipates a low- to mid-single digit percentage decline in this division&rsquo;s sales due to the patent expiries.</p>\n<h2>'Promising late-stage assets'</h2>\n<p>Werner Baumann, chairman of the board of management, said that the group was confident that the division can return to sustainable growth in 2025, with plans to further strengthen the US business and in China, and continuing to develop the research pipeline.</p>\n<p>&ldquo;We are well under way with the market introduction of our promising late-stage pipeline assets,&rdquo; he said.</p>\n<p>These include, in particular, the cancer drug Nubeqa (darolutamide), the cardiovascular drugs vericiguat &ndash; marketed in the USA under the brand name Verquvo &ndash; and finerenone, along with elinzanetant for the non-hormonal treatment of frequent symptoms of the menopause.</p>\n<h2>Long-term investments in cell and gene</h2>\n<p>Bayer is also making substantial progress in strengthening its innovation capabilities by establishing a leading position in cell and gene therapy and pursuing bolt-on acquisitions, partnerships and licensing agreements.</p>\n<p>Last year alone, the company concluded more than 25 collaboration and licensing agreements and acquisitions in its Pharmaceuticals unit, most notably the takeover of the gene therapy company AskBio for up to $4 billion.</p>\n<p>Bayer also announced promising initial results achieved by its cell therapy subsidiary BlueRock Therapeutics recently.</p>\n<p>&ldquo;We have begun clinical trials with a new therapeutic approach for Parkinson&rsquo;s, a neurological disorder, that could hopefully pave the way for major advances in the battle against this debilitating illness &ndash; this represents a major step forward for the entire field of stem cell therapy,&rdquo; Mr Baumann said.</p>\n<p>&nbsp;</p>", "date": "2021-03-11 11:28:00", "meta_title": NaN, "meta_keywords": "Bayer, bounce, sales, Pharmaceuticals, company, patent, decline, confident, anticipates, pharma, blip, blockbusters, established, expirations, German, Eyle", "meta_description": "German company Bayer is confident that it can bounce back from a decline in the Pharmaceuticals division\u00e2\u0080\u0099s sales in 2024 due to the patent expirations for estab", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-11 11:19:58", "updated": "2021-03-11 12:39:46", "access": NaN, "url": "https://www.thepharmaletter.com/article/bayer-anticipates-immediate-pharma-bounce-back-after-2024-blip", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bayer_flags_large.jpg", "image2id": "bayer_flags_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Cardio-vascular, Cell and Gene Therapy, Oncology, Ophthalmics, Women's health", "topic_tag": "Financial, Management, Research", "geography_tag": "Germany", "company_tag": "Bayer, BlueRock Therapeutics", "drug_tag": "Eylea, finerenone, Xarelto", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-11 11:28:00"}